Welichem Filed Quarterly Report for Period Ended February 29, 2008BURNABY, BC, April 28 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI - News), announced today that the Company filed its third quarter financials and MD & A. The net losses for the 3-month period ended February 29, 2008 were $618,287 (2007- $812,781) and 1 cent per share (2007 - 2 cents per share). The net losses for the 9-month period ended February 29, 2008 were $1,702,294 (2007- $2,511,360) and 2 cents per share (2007 - 5 cents per share). About Welichem Biotech Inc. Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer. ON BEHALF OF THE BOARD The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements. For further information York Yingping Guo, President and Chief Executive Officer, Tel.: (604) 432-1703, Email: yorkguo@welichem.com Yan Chen, Business Development Manager, Tel.: (604) 432-1703, Email: investors@welichem.com -------------------------------------------------------------------------------- Source: Welichem Biotech Inc. |